Growth Hormone Pretreatment in Poseidon Type IV Undergoing ICSI Using Minimal Induction Protocol: A Randomized Controlled Trial | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 154, Volume 99, Issue 1, April 2025, Page 2469-2472 PDF (289.95 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2025.435792 | ||||
 View on SCiNiTO | ||||
| Abstract | ||||
| Background: Poor ovarian reserve (POR) makes it harder for assisted reproductive technology (ART) to succeed, often resulting in lower success rates for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatments. Researchers are constantly looking for new ways to improve how ovaries respond and to increase pregnancy rates for these patients. Objective: This clinical trial aimed to investigate whether growth hormone (GH) pre-treatment could improve the success rates of IVF/ICSI for women with poor ovarian reserve. Patients and methods: This clinical trial included 132 participants who were 35 years or older and had an anti-mullerian hormone (AMH) level under 1.2 ng/mL. These criteria categorize them as POSEIDON group 4, meaning they have poor ovarian reserve. The participants were split evenly into two groups: One receiving growth hormone (GH) as a pre-treatment (GH+ group) and a control group without GH (GH- group), with 66 patients in each. To minimize the influence of other factors, a one-to-one case-control matching was employed. All patients underwent ART using minimal ovarian stimulation protocols. Results: Adding GH as an extra treatment didn't significantly improve how ovaries responded (like the number of eggs retrieved) or increase the live birth rate for the overall group of patients with poor ovarian reserve. Even when specifically analyzing patients meeting the POSEIDON group 4 criteria, GH adjuvant therapy still showed no benefit in terms of promoting live births. Conclusion: This study concluded that using GH pretreatment as an additional therapy did not significantly improve clinical outcomes, specifically the live birth rate, for patients classified under POSEIDON group 4. These are women aged 35 or older with poor ovarian reserve who underwent ICSI treatment using minimal ovarian stimulation protocols. This suggests that for this specific group of patients, adding GH pretreatment may not be an effective strategy to increase their chances of a live birth. | ||||
| Keywords | ||||
| Growth hormone; Poor ovarian reserve; POSEIDON criteria | ||||
|
Statistics Article View: 42 PDF Download: 44 |
||||
